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AbstrAct
Objectives Delirium is an underdiagnosed, severe and 
costly disorder, and 30%–40% of cases can be prevented. 
A fully automated model to predict delirium (DEMO) in 
older people has been developed, and the objective of this 
study is to validate the model in a hospital setting.
setting Secondary care, one hospital with two locations.
Design Observational study.
Participants The study included 450 randomly selected 
patients over 60 years of age admitted to Zuyderland 
Medical Centre. Patients who presented with delirium on 
admission were excluded.
Primary outcome measures Development of delirium 
through chart review.
results A total of 383 patients were included in this 
study. The analysis was performed for delirium within 1, 3 
and 5 days after a DEMO score was obtained. Sensitivity 
was 87.1% (95% CI 0.756 to 0.939), 84.2% (95% CI 0.732 
to 0.915) and 82.7% (95% CI 0.734 to 0.893) for 1, 3 
and 5 days, respectively, after obtaining the DEMO score. 
Specificity was 77.9% (95% CI 0.729 to 0.882), 81.5% 
(95% CI 0.766 to 0.856) and 84.5% (95% CI 0.797 to 
0.884) for 1, 3 and 5 days, respectively, after obtaining the 
DEMO score.
conclusion DEMO is a satisfactory prediction model 
but needs further prospective validation with in-person 
delirium confirmation. In the future, DEMO will be applied 
in clinical practice so that physicians will be aware of 
when a patient is at an increased risk of developing 
delirium, which will facilitate earlier recognition and 
diagnosis, and thus will allow the implementation of 
prevention measures.
IntrODuctIOn
A delirium or acute confused state is a tran-
sient attention and cognition disorder that 
develops over a short period of time and 
occurs mainly in hospitalised patients and 
people aged 60 years and over. Delirium 
is an underdiagnosed, severe (increased 
mortality), costly and often preventable 
disorder.1–3 Its severity and symptoms can 
vary considerably, but the main features are 
impaired cognitive and sensory functions, 
reduced consciousness and diminished 
attention. In addition, it is often accompa-
nied by problems with psychomotor activity, 
the circadian rhythm and emotions.
The prevalence and incidence of delirium 
in the general population differ widely 
depending on the setting. The overall prev-
alence in the community is estimated to be 
1%–2%. In a hospital setting, this prevalence 
increases to 10%–31% at the time of hospital 
admission and 3%–29% during hospitalisa-
tion. The incidence increases up to 87% when 
more specialised populations, such as the 
elderly and people in postoperative, inten-
sive care and/or palliative care, are consid-
ered.4–11 In 30%–40% of cases, delirium is 
preventable, which, along with its associated 
high costs (ranging from US$164 billion to 
US$182 billion per year), makes it a perfect 
target for interventions by healthcare profes-
sionals.1 4 12–15 As a result, a great number of 
screening tools have been developed and 
are widely used to detect the early onset 
of delirium, which can in turn allow treat-
ment measures to be introduced in a timely 
manner.16–21 These tools help healthcare 
professionals to establish and quantify symp-
toms associated with delirium.19–23 Once the 
diagnosis has been established, the under-
lying medical condition can be targeted, and 
delirium can be managed appropriately.
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Research
strengths and limitations of this study
 ► A high risk of delirium can be predicted electronically 
by using DEMO (DElirium MOdel) with reasonably 
good sensitivity and specificity.
 ► DEMO can be applied in clinical practice to facilitate 
earlier recognition and diagnosis of delirium.
 ► Important factors that could predict delirium 
(previous delirium, cognitive impairment, severity 
of disease, visual impairment, etc) are not included 
in this model because these data are not yet 
electronically available.
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box DElirium MOdel (DEMO) and cut-off point
DEMO score=1/(1+e−(linear predictor))
 DEMO score ≥14.1%→increased risk at delirium
 DEMO score <14.1% → no increased risk at delirium
Linear predictor = -8.823+(0.081×V1)+(0.031×V2)+(0.248×V3)+(1.1
23×V4)+(0.286×V5)+(1.963×V6)+(0.359×V7)+(1.199×V8)+(0.413×V
9)+(0.103×V10)
 V1=age (years)
 V2=polypharmacy (number of drugs)
 V3=anxiolytics (ATC N05B)
 V4=anti-dementia (ATC N06D)
 V5=antidepressives (ATC N06A)
 V6=anti-Parkinson’s agents (ATC N04)
 V7=antidiabetic (ATC A10)
 V8=psychopharmaca (ATC N05A)
 V9=analgetics (ATC N02A)
 V10=sleep medication (ATC N05C)
ATC, Anatomical Therapeutic Chemical classification system (https://www.
whocc.no/atc_ddd_index/).
There is no effective treatment for delirium.24 25 
Preventing delirium is by far a more effective strategy to 
improve patient outcomes.1 4 26–29 Risk models have been 
used to identify patients at higher risk for delirium devel-
opment because these patients would most likely benefit 
from delirium prevention. These models are based on 
manual evaluation of individual risk factors and may be 
difficult to implement, so automated models are prefer-
able and more feasible.30–34
screening instrument
A fully automated model to predict delirium in older 
people (aged over 60 years) was developed at Zuyderland 
Medical Centre. This DElirium MOdel (DEMO) uses only 
electronically available data to predict the occurrence of 
delirium. The predictive variables include age, polyphar-
macy and the use of antidementia drugs, antidepressants, 
anti-Parkinson’s agents, antidiabetic drugs, analgesia and/
or sleeping tablets (see box). This model can be applied 
hospital-wide and has an area under receiver operating 
characteristic (measure for model prediction quality) 
value of 0.770 (95% CI 0.736 to 0.804) with a sensitivity of 
78.2% and a specificity of 63.7%, when 14.1% is used as a 
cut-off value for the predicted probability of developing 
delirium. DEMO was developed retrospectively but has 
not yet been validated.4
Therefore, the objective of this study is to validate 
DEMO in a hospital setting. To do so, the system’s accu-
racy (main study parameter), that is, sensitivity (propor-
tion of delirium patients who test positive) and specificity 
(proportion of non-delirium patients who test negative), 
will be calculated. In addition to these parameters, the 
positive predictive value (PPV), negative predictive value 
(NPV), positive and negative likelihood ratios (LR+, LR−) 
with their 95% CI will be computed.
MEthODs
This is an observational study of the ability of DEMO 
to predict delirium in an elderly hospital population. It 
was conducted in Zuyderland Medical Centre (locations 
Sittard and Heerlen) in the period from January 2016 to 
October 2016.
DEMO involves a daily analysis of all hospitalised 
patients aged ≥60 years at the different wards and predicts 
whether a patient is at risk of developing delirium in a 
24-hour postanalysis period. The electronic patient 
record (EPR) was accessed at a later date to check for 
delirium diagnosis. In this study, DEMO was calculated 
prospectively, but the outcome was ascertained by chart 
review retrospectively.
Although delirium diagnosis was determined by chart 
review, delirium documentation in our hospital is robust. 
At admission, patients are routinely screened for delirium, 
both in the emergency department and in the ward. The 
first screening is performed by a checklist (Inspectie voor 
de Gezondheidszorg=Dutch Healthcare Inspectorate, 
Veiligheids management systeem=Safety Management 
System and Dutch guideline for delirium).35 36 This check-
list consists of three questions: does the patient need 
help with self-care?, has the patients previously suffered 
a delirium?, does the patients suffer from memory disor-
ders? When one of the questions is positively answered, the 
patient is at risk of developing delirium; in this case, the 
Delirium Observation Screening Scale (DOSS) method20 
is used to evaluate whether a patient has delirium and it is 
subsequently noted in the chart.
Patients aged over 60 years who were admitted to 
Zuyderland were eligible for enrolment. From all 
patients admitted between 31 December 2015 and 
31 October 2016, 450 patients were randomly selected 
(using https://www. randomlists. com/ team- generator) 
and their charts extracted for review. Patients who, based 
on chart review, presented with delirium on admission 
were then excluded (see online supplementary figure 1).
A search in the EPR was performed according to patient 
and date by using the following search terms: ‘delirium’, 
‘delirious’, ‘agitation’, ‘agitated’, ‘confused’, ‘confusion’, 
‘restlessness’, ‘disturbed’, ‘disorientation’, ‘disoriented’, 
‘apathy’, ‘hallucination’, ‘mistrust’, ‘haloperidol’ and 
‘delirium prevention measures’. These search terms were 
discussed with an internist geriatrician, a professor of 
geriatric medicine and a professor of geriatric psychiatry.
The search was performed by first identifying where the 
different words appeared in the EPR, and then, if any of 
these words appeared, the whole EPR during the admis-
sion period was read and interpreted by two authors (KH 
(internist geriatrician) and CMG (hospital pharmacist)) 
to determine whether it was truly a delirium diagnosis. 
All notes were reviewed, including notes by physicians, 
nurses, physiotherapists and speech therapists. During 
the study, treating healthcare professionals (physicians, 
nurses, etc) were blinded to DEMO scores in order to 
avoid bias. If a diagnosis of delirium could not be estab-
lished for a patient as a result of insufficient information 
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Table 1 Test results of the prediction model (DEMO positive or negative) and diagnosis (delirium during admission or 
no delirium during admission) within 1, 3 and 5 days after DEMO analysis
Delirium 
within 1 day 
after DEMO
No delirium 
within  
1 day after DEMO
Delirium 
within 3 days 
after DEMO
No delirium 
within 3 days 
after DEMO
Delirium 
within 5 days 
after DEMO
No delirium 
within 5 days 
after DEMO
DEMO positive 54 71 69 56 81 44
DEMO negative 8 250 11 247 17 241
DEMO, DElirium MOdel.
Table 2 Estimates of the prevalence, sensitivity, specificity, PPV, NPV and LRs with corresponding 95% CIs 1, 3 and 5 days 
after DEMO analysis
Day 1 after DEMO analysis Day 3 after DEMO analysis Day 5 after DEMO analysis
Estimated 
value
95% CI
Estimated 
value
95% CI
Estimated 
value
95% CI
Lower 
limit 
Upper 
limit
Lower 
limit
Upper 
limit Lower limit
Upper 
limit
Prevalence 16.2% 0.127 0.204 18.8% 0.150 0.221 25.6% 0.213 0.303
Sensitivity 87.1% 0.756 0.939 84.2% 0.732 0.915 82.7% 0.734 0.893
Specificity 77.9% 0.729 0.822 81.5% 0.766 0.856 84.5% 0.797 0.884
PPV 43.20%* 0.345 0.524 51.3%* 0.419 0.607 64.8%* 0.557 0.730
NPV 96.90% 0.938 0.986 95.7% 0.922 0.977 93.4% 0.895 0.960
LR+ 3.938 3.140 4.939 4.560 3.526 5.898 5.354 4.020 7.129
LR− 0.166 0.087 0.317 0.193 0.112 0.332 0.205 0.133 0.316
*PPV: statistically different p<0.001 for all three comparisons (1 vs 3 days, 1 vs 5 days, 3 vs 5 days).
DEMO, DElirium MOdel; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
in the chart, this patient was excluded from the analysis. 
The date of delirium onset was determined by chart 
review.
Delirium diagnosis based on chart review was then 
compared with the risk score from DEMO. The DEMO was 
dichotomised into two groups: high risk ≥14.1%,4 and low 
risk <14.1% for this analysis. A two-by-two table was then 
constructed to calculate true positive (TP), true negative 
(TN), false positive (FP) and false negative (FN) rates.
The predictive value of DEMO was determined for 
delirium developing within 1, 3 and 5 days after the 
DEMO score was calculated. It had been developed to 
predict delirium within the next 24 hours, but here we 
wished to also investigate whether its predictive value 
could be extended to 3 or 5 days.
In the study wherein the DEMO was developed, an 
incidence rate of 17.4% was used.4 Given the assumption 
of the same sensitivity of 0.75 (75%), we calculated that 
33 delirium patients were needed based on the require-
ment that the lower limit of 95% CI would be at least 
60% (width of 95% CI ≤0.30 (30%)). With regard to the 
specificity, the number of non-delirium patients would be 
much larger than the number of delirium patients, and 
hence, the width of the 95% CI for specificity would be 
<0.30.
It was assumed that at least 332 patients would be 
needed to identify 33 delirium patients. Taking into 
account the exclusion criteria and the possibility of 
a smaller percentage of patients who would develop 
delirium, a sufficient number of patients were screened 
to obtain 33 delirium patients (ie, 450 patients).
The sensitivity, specificity, PPV, NPV, LR+, LR− with 
corresponding 95% CIs were calculated with the use of 
an online calculator (http:// vassarstats. net/ clin1. html).
The differences in PPV and NPV over time were tested 
using McNemar’s test. The differences in age and gender 
between delirium and non-delirium groups were tested by 
using the independent-samples t-test and χ2 test, respec-
tively. IBM SPSS statistics for Windows (V.23.0) was used 
to perform these tests. A two-sided p≤0.05 was considered 
statistically significant.
rEsults
The study lasted 8 months, for 450 patients chart review 
was undergone. Finally, a total of 383 patients were 
included, as 21 patients presented with delirium at admis-
sion, and for 46 patients there was insufficient information 
to determine delirium status (see online supplementary 
figure 1). The results of the diagnostic test (TP/FP/FN/
TN) for 1, 3 and 5 days after DEMO analysis are shown 
in table 1. The analysis, including prevalence estimates, 
sensitivity, specificity, PPV, NPV and LRs, is presented 
in table 2. Although sensitivity decreased and specificity 
increased if the period increased from 1 day to 3 or 5 days 
after DEMO score was obtained, all values were rather 
high (sensitivity ≥0.827, specificity ≥0.779). PPV was statis-
tically different p<0.001 for all three comparisons (1 vs 
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3 days, 1 vs 5 days, 3 vs 5 days), NPV was not statistically 
different p=0.25, 0.004, 0.031 for 1 vs 3 days, 1 vs 5 days 
and 3 vs 5 days, respectively.
Patients who developed delirium within 5 days were 
significantly older (mean age 83.9 (SD 7.8)) compared 
with those who did not develop a delirium within 5 
days (mean age 73.9 (SD 9.1); p<0.001). There was no 
significant difference in the percentage of males within 
the delirium and non-delirium groups (50.0% vs 50.1%, 
p=0.911).
DIscussIOn AnD cOnclusIOn
In the current study, a previously developed model for 
predicting delirium has been validated. DEMO was calcu-
lated prospectively, and the outcome was ascertained by 
chart review retrospectively. Based on the current data 
and the high sensitivity and specificity, it can be concluded 
that DEMO is a satisfactory prediction model.
Another strength of DEMO is that it predicts delirium 
within 5 days postanalysis on a daily basis. This is a novel 
concept, as most delirium prediction rules apply at admis-
sion but not daily. Even though it is not clear whether 
there is a definite advantage to predicting delirium on a 
daily basis, as this could lead to information overload, it 
could eventually be something that is tracked along with 
vital signs and intake/output.
We found sensitivity and specificity rates that were 
higher than reported in the study by de Wit et al, which 
may be because his study only checked the patients’ 
medical history for delirium and not the entire EPR. 
Moreover, de Wit et al had performed the search merely 
on the diagnosis of delirium. In the current study, the full 
EPR during the admission period was taken into account, 
and a wider set of terms was considered for delirium 
diagnosis. Furthermore, in the current study, in those 
cases in which delirium was not clear, these patients were 
excluded, whereas such patients had been included in 
the development of the delirium model.4
The present study does present some limitations. 
First, the validation of the DEMO depends on how and 
when a healthcare professional reports that a patient 
has developed delirium. It is well known that documen-
tation of delirium is poor since the majority of delirium 
remains unrecognised by clinical teams.37 We therefore 
performed a wider search considering other words that 
might suggest delirium as delirium diagnosis and read 
through the whole EPR during the admission period. The 
number of delirium patients is noticeably higher than 
originally found, which can be explained by the search 
we performed. The DEMO is merely an aid to detect 
delirium, not a diagnostic tool by itself. Furthermore, for 
46 patients there was insufficient information in the chart 
to determine delirium status, which could influence the 
generalisability of the present study.
In addition, as mentioned in the study by 
Inouye et al,38 using a chart review method has some 
limitations as it has a 30% false-positive rate and thus it 
is possible that patients with delirium at admission may 
have been included in the non-delirious cohort due to 
poor documentation in the chart.
Furthermore, the checklist used to screen the patients 
is a non-validated tool. Nevertheless, after that first check, 
the DOSS is used. The DOSS method is a validated 
method used by nurses to screen for delirium. Its sensi-
tivity ranges from 89% to 100% and its specificity ranges 
from 88% to 96.6%.20 39 40 The DOSS scores and its conclu-
sion (delirium/non-delirium) are recorded in the chart. 
In that way, and taking into account that the chart is a 
complete document in which different healthcare profes-
sionals note their findings, makes the outcome more reli-
able and strengthens the validity of the present study.
Another limitation of the present study is that this is 
a single-centre study (two hospital locations) located in 
the Netherlands and may not be generalisable in other 
settings.
The DEMO uses only electronically available data. 
Other important factors that could predict a delirium 
(previous delirium, cognitive impairment, severity of 
disease, visual impairment, etc) are not included in this 
model because they were not electronically available. If 
these data were also made electronically available, the 
predictive quality of DEMO could be improved.22 23 27 30 
Taking into account that the registration of such factors 
is becoming increasingly important and mandatory, it is 
only a matter of time until these important factors can 
be used in the DEMO.2 3 In addition, DEMO already uses 
an alternative way of identifying cognitive impairment by 
including medications used for dementia.
The DEMO is a fully automated satisfactory prediction 
model that predicts delirium up to 5 days after analysis. 
The next step is to validate the DEMO in a cohort in 
which the outcome of delirium would be prospectively 
assessed in person and to use DEMO for retrospective 
measurements. In the future, DEMO will be applied to 
clinical practice so that physicians are alerted when a 
patient is at increased risk of developing delirium. This 
will facilitate earlier recognition and diagnosis and, thus, 
the implementation of prevention measures.
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